Document text
Principal Investigator: Pamela Frischmeyer-Guerrerio
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $612,630
Funding agency: National Institute of Allergy and Infectious Diseases
The SARS-CoV-2 virus has incited a global pandemic leading to profound loss of human life and tremendous economic and social upheaval. The FDA has now approved two mRNA vaccines produced by Pfizer-BioNTech and Moderna that were found to be highly effective in Phase 3 trials at preventing COVID-19. The active ingredient in both vaccines is nucleoside-modified mRNA encoding the SARS-CoV-2 spike protein. Both vaccines exhibited a favorable safety profile, with most side effects being mild to moderate in severity and including pain, swelling, and redness at the injection site, headache, fatigue, fever, chills, nausea, myalgia, arthralgia, and lymphadenopathy.
However, within days of administration of the vaccines to healthcare workers in both the United States (US) and United Kingdom (UK), multiple reports of severe allergic reactions emerged. The overall rate of anaphylaxis to the mRNA COVID-19 vaccines is currently estimated at approximately 2.5-10 cases per million doses administered, which is higher than that reported for vaccines in general, 1.31 (95% CI, 0.90-1.84) cases per million vaccine doses, using similar criteria for defining anaphylaxis.
At this point, we do not know the antigen or underlying mechanisms responsible for triggering allergic reactions to the COVID-19 mRNA vaccines. As a result, there is no diagnostic test that can be used to reliably predict whether a given individual is at risk for having an allergic reaction to these vaccines. This has resulted in considerable confusion and lack of consensus in the field of allergy on how to advise patients who reacted to the mRNA COVID-19 vaccines.
Current CDC guidelines contraindicate subsequent doses of the mRNA vaccine in patients with a severe allergic reaction or a non-severe immediate allergic reaction to a prior dose of mRNA vaccine or known history of allergy to the components of the vaccine and recommend vaccination with alternative platforms. Presumably these individuals will also not be eligible to receive any future vaccines using the mRNA platform, which may have significant consequences as this technology is being utilized both for other infectious diseases (influenza, HIV, RSV, Herpes, CMV and Zika are already undergoing early trials) and cancer (studies ongoing in treatment of solid tumors and melanoma in conjunction with immunotherapy). For these reasons, a better understanding of the mechanisms responsible for allergic reactions to the mRNA COVID vaccines is critically needed in order to reassure the public and to provide evidence-based guidance on who can safely receive these vaccines, including a second and booster dose in those individuals who experienced a reaction to the first dose.
In FY22, we have continued enrollment on our clinical trial to assess the safety of administering the Pfizer-BioNTech mRNA COVID-19 vaccine to individuals 18-69 years of age who experienced a systemic allergic reaction to the first dose of either the Moderna or Pfizer-BioNTech mRNA COVID-19 vaccines. This is a single-site study that is being conducted in the Intensive Care Unit (ICU) at the NIH Clinical Center (CC). The primary objective of the study is to assess the proportion of participants who develop a systemic allergic reaction (Consortium for Food Allergy Research (CoFAR)) grade 2 reaction and above regardless of tryptase, and CoFAR grade 1 with elevated tryptase (1.2 X baseline plus 2 ng/mL) to the Pfizer-BioNTech vaccine after previously demonstrating a systemic allergic reaction (CoFAR Grade 2 or 3 reaction regardless of tryptase OR Grade 1 reaction with elevated tryptase (1.2 X baseline plus 2 ng/mL) to the first dose of either the Moderna or Pfizer-BioNTech mRNA COVID-19 vaccines. Individuals who experience no or only a mild allergic reaction to the second dose of the vaccine have the opportunity to receive a booster dose 5 months later. A broad range of mechanistic studies are also being performed to learn more about the mechanisms underlying these reactions.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><AIDS Virus><Aching muscles><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Age-Years><Allergic Reaction><Allergic to food><Allergy><Allergy to food><Anaphylactic Reaction><Anaphylactic Shock><Anaphylaxis><Antigens><Arthralgia><BNT 162b2><BNT162b2><CDC><CMV><COVID><COVID-19><COVID-19 S protein><COVID-19 prevention><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 S protein><COVID19 prevention><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cancers><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Cephalalgia><Cephalgia><Cephalodynia><Clinical Trials><CoV disease><CoV-2><CoV2><Communicable Diseases><Confusion><Confusional State><Consensus><Cranial Pain><Cytomegalovirus><Diagnostic tests><Disease><Disorder><Dose><Economics><Enrollment><Exhibits><Fatigue><Fever Chills><Food Allergy><Food Hypersensitivity><Future><Goals><Grippe><Guidelines><HCMV><HIV><Head Pain><Headache><Health Care Providers><Health Personnel><Healthcare Providers><Healthcare worker><History><Human><Human Immunodeficiency Viruses><Hypersensitivity><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Influenza><Injections><Intensive Care Units><Joint Pain><LAV-HTLV-III><Lack of Energy><Learning><Life><Lymphadenopathy-Associated Virus><Malignant Melanoma><Malignant Neoplasms><Malignant Tumor><Mental Confusion><Messenger RNA><Modern Man><Muscle discomfort><Muscle pain><Muscle pain/fibrositis><Muscle sorenesss><Myalgia><Myalgic><Myodynia><Myoneuralgia><Myosalgia><NIH><National Institutes of Health><Nausea><Nucleosides><Pain><Painful><Participant><Patients><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Public Health><RNA vaccine><RNA-based vaccine><Reaction><Recording of previous events><Redness><Reporting><Research><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Salivary Gland Viruses><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severities><Site><Solid Neoplasm><Solid Tumor><Swelling><Technology><Tryptase><United Kingdom><United States><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States National Institutes of Health><Vaccination><Vaccine Production><Vaccines><Virus><Virus-HIV><Wuhan coronavirus><ZIKA><adenopathy><booster dose><booster shot><booster vaccine><clinical center><corona virus disease><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 prevention><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 prevention><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cytomegalovirus group><enroll><evidence base><experience><hCoV19><head ache><health care personnel><health care worker><health provider><health workforce><healthcare personnel><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lung tryptase><lymphadenopathy><mRNA><mRNA vaccine><mRNA-based vaccine><malignancy><mast cell protease II><mast cell tryptase><medical personnel><melanoma><nCoV2><neoplasm/cancer><pandemic><pandemic disease><phase 3 trial><phase III trial><prevent><prevent COVID-19><prevent COVID19><prevent coronavirus disease 2019><preventing><produce vaccines><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><side effect><skin tryptase><social><treatment provider><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus>